Choose your country

Grindeks search

International
Show pages

TOP Products

  • Mildronate®

    Grindeks’ best-selling product is the company’s original product, the anti-ischemic metabolic agent Mildronate®, developed in the middle of 1970’s at the Latvian Institute of Organic Synthesis by the group of scientists at the head of Professor Ivars Kalvins.

    Read more

    Grindeks’ best-selling product is the company’s original product, the anti-ischemic metabolic agent Mildronate®, developed in the middle of 1970’s at the Latvian Institute of Organic Synthesis by the group of scientists at the head of Professor Ivars Kalvins.

    Since 1988, gaining wide recognition among cardiologists and other health care professionals, Mildronate®, besides its homeland Latvia, has been registered in 16 countries, mostly the CIS region.

    For many years, the growth of Grindeks was closely linked to the advancement of the product. Since 2000’s, Mildronate® has repeatedly been recognised as the best export product of Latvia, receiving awards from external healthcare communities as well.

    Mildronate® belongs to Grindeks’ vertically integrated products, so the company provides complete manufacturing from its API, meldonium, to the FDF – tablets, capsules, and injections. In the meantime, Grindeks is also the world’s leading manufacturer of meldonium.

    To learn more about Mildronate®, please visit our website Mildronate.com (for healthcare professionals only).


    Read less
  • Ftorafur®

    Ftorafur® – a chemotherapeutic drug for the treatment of malignant tumours, particularly gastric, colorectal and breast cancer, is the other Grindeks’ original product.

    In 1964, Ftorafur® was synthesized at the Institute of Organic Synthesis of the Latvian Aca ...
    Read more

    Ftorafur® – a chemotherapeutic drug for the treatment of malignant tumours, particularly gastric, colorectal and breast cancer, is the other Grindeks’ original product.

    In 1964, Ftorafur® was synthesized at the Institute of Organic Synthesis of the Latvian Academy of Sciences, and its discovery could be considered as an essential step in the development of chemotherapy. Experimental and clinical investigations of Ftorafur® took place in the USSR, Japan, USA and some European countries. Since 1969, an active co-operation is developed with Japanese companies Taiho Pharmaceutical and Iskra.

    Ftorafur® is registered in Latvia, Lithuania, Hungary, Czech Republic, Russia and other CIS countries.

    Ftorafur®’s active pharmaceutical ingredient tegafur is exported to Japan since 1972, though the final dosage form – 400 mg capsules – are sold in Baltic and CIS countries, Japan, as well as in the markets of several European countries.
    Grindeks manufactures and exports Ftorafur® for more than 40 years and continues to develop scheme of its optimal usage.


    Read less
  • Oxytocin-Grindeks

    Oxytocin, a hormone that is used as a medication to facilitate childbirth, reduce postpartum bleeding, as well as to stimulate breastfeeding, is one of the vertically integrated products by Grindeks, namely, the company produces both the active pharmaceutical ingredient and th ...
    Read more

    Oxytocin, a hormone that is used as a medication to facilitate childbirth, reduce postpartum bleeding, as well as to stimulate breastfeeding, is one of the vertically integrated products by Grindeks, namely, the company produces both the active pharmaceutical ingredient and the final dosage form – injection. Thanks to successful marketing and sales strategy the demand for the product is highly increasing. Listed on the World Health Organization (WHO) List of Essential Medicines and has been listed under an Expression of Interest issued by the WHO pre-qualification of Medicines Programme (PQP).


    Read less